2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
19
Neoplasm Metastasis
2
Prostatic Neoplasms, Castration-Resistant
1
Prostate Adenocarcinoma
1
Pain
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Fatigue
1
Castration-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Biochemical Recurrent Prostate Cancer
1
Interventions
radium Ra 223 dichloride
2
pembrolizumab
2
enzalutamide
2
abiraterone
2
Injections
2
Abiraterone Acetate
2
niraparib
1
efineptakin alfa
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
Solutions
1
Radium-223
1
Prednisone
1
Pluvicto
1
PSMA-11
1
Lutetium-177
1
Lutetium
1
Docetaxel
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
Radium-223
×
Clear all
NCT03896984
2021-12-29
PHENIX
Bayer
Completed
346 enrolled